Ocuphire Pharma Inc. (OCUP) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Ocuphire Pharma Inc. (OCUP)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.17

-0.16 (-12.03%)

At close: Oct 23, 2024, 8:00 PM

undefined% (undefined)

Bid	n/a
Market Cap	31.74M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.54
PE Ratio (ttm)	-2.17
Forward PE	n/a
Analyst	Buy

Ask	n/a
Volume	675,971
Avg. Volume (20D)	139,910
Open	1.33
Previous Close	1.33
Day's Range	1.07 - 1.36
52-Week Range	1.07 - 3.40
Beta	undefined

About OCUP

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induc...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 10, 2005

Employees 14

Stock Exchange NASDAQ

Ticker Symbol OCUP

Website https://www.ocuphire.com

Analyst Forecast

According to 3 analyst ratings, the average rating for OCUP stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

News

2 months ago · benzinga.com

Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal

On Wednesday, Ocuphire Pharma, Inc. OCUP announced the all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs).

2 months ago · businesswire.com

Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Ocuphire (Nasdaq: OCUP) for possible breaches of fiduciary duty and other violations of law in its transaction with Opus Genetics. Click here to ...

5 months ago · zacks.com

Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates

Ocuphire Pharma, Inc. (OCUP) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago.